Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension

Registry ID

EUCTR2009-016738-28

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

AZIENDA OSPEDALIERA PISANA

Start date

2009-12-11

Last update

2026-08-16

Conditions

• essential hypertension

Summary

To evaluate the effect of aliskiren on endothelial dysfunction, nitric oxide availability and reactive oxygen species production at the level of the forearm microcirculation in patient with essential hypertension.

Locations

• , , Italy

View on source registry